Bedrijfsoverzicht
Xenetic Biosciences, Inc. is a biopharmaceutical entity dedicated to advancing immune-oncology technologies specifically designed to treat various forms of cancer. The company's core operational focus involves the utilization of DNase technology which targets neutrophil extracellular traps (NETs), biological structures known to facilitate cancer growth, metastasis, and progression while also playing a role in the efficacy of immunotherapy and chemotherapy treatments. Operating within the Healthcare sector and the Biotechnology industry, the firm represents a specialized segment of the market where innovation in drug delivery and molecular targeting is critical for therapeutic advancement. The company currently maintains a market capitalization of $7.01 million, generates annual revenue of $2.98 million, and employs a workforce of 2 individuals. These financial figures indicate that Xenetic Biosciences operates on a very small scale relative to large-cap pharmaceutical peers, suggesting a nascent stage of development where capital efficiency is paramount and the company is likely still in the early phases of commercializing its immune-oncology platforms.
Financiële gezondheid
For the trailing twelve months, the company reported revenue of $2.98 million, recorded a net income of $-2,680,860, and has not reported an EBITDA figure. The substantial gap between the positive revenue of $2.98 million and the significant negative net income of $-2,680,860 reveals a cost structure characterized by high operating expenses that currently exceed total sales, which is typical for early-stage biotechnology firms investing heavily in research and development. The company's free cash flow stands at $-1,377,405, indicating a net outflow of cash that necessitates external financing or the use of existing reserves to fund ongoing operations and growth initiatives. Despite the negative free cash flow, the balance sheet shows a cash reserve of $7.88 million with zero recorded debt, providing a significant liquidity buffer to support its cash burn rate. The company's margins reflect its developmental stage, boasting a gross margin of 100.0% due to the absence of cost of goods sold, while the operating margin sits at -81.3% and the profit margin is -90.1%, highlighting the heavy expense burden relative to current revenue generation. Total cash of $7.88 million significantly outweighs total debt of $0, confirming a highly conservative balance sheet structure with no leverage. The current ratio is 8.32, which indicates an exceptionally strong short-term liquidity position where current assets are more than eight times the value of current liabilities. Regarding return metrics, the Return on Equity is -40.0% and the Return on Assets is -23.2%, figures that reveal management is currently generating negative returns on the capital base as the company prioritizes long-term asset accumulation and technology advancement over immediate profitability.
Waarderingsbeoordeling
The company has a trailing P/E ratio of N/A and a forward P/E of -4.64, the discrepancy implying that the firm is currently unprofitable and traditional earnings-based valuation multiples are not applicable to assess its current market value. The price-to-book ratio is 0.95, suggesting that the market values the company's equity at a discount relative to its book value, which is often observed in biotech firms where intangible assets and pipeline potential are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.36 and the EV/EBITDA of N/A provide insight into the company's pricing relative to its top-line growth, indicating that investors are willing to pay over twice the annual revenue for a company that has not yet achieved positive earnings. The stock's price action has been volatile, with a 52-week high of $13.93 and a 52-week low of $1.90, meaning the current valuation sits at a specific point within this wide range that reflects significant market sentiment shifts regarding its clinical pipeline. The beta value is 2.21, indicating that the stock price is expected to be approximately 121% more volatile than the broader market, reflecting the high risk premium associated with small-cap biotechnology equities.
Growth & Income
Xenetic Biosciences reported a revenue growth of 18.1% year-over-year, while the earnings growth rate is N/A due to the company's ongoing losses, implying that top-line expansion is occurring without yet translating into bottom-line profitability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are theoretically retained or, more accurately in this case, the company is reinvesting its cash reserves directly into research and development rather than distributing income to shareholders. The overall growth and income profile is defined by rapid top-line expansion funded by cash reserves rather than dividend income, positioning the firm for potential future commercialization rather than current income generation. This reinvestment strategy is consistent with the industry norms for early-stage biopharmaceutical companies that require substantial capital injection to advance their immune-oncology technologies toward market approval.